Faex Health Brings AI-Powered Digestive Health Monitoring to HLTH 2026, Advancing the Conversation Around Preventive Healthcare

Co-Founder and CEO Landon Nattrass joins healthcare innovators in Las Vegas 
to explore how artificial intelligence, continuous monitoring and accessible technology can support earlier intervention and more connected care

LAS VEGAS, Nov. 16, 2026 — Faex Health, a digital health company that has developed AI-powered tools to help people better understand and track digestive wellness, is showcasing its groundbreaking app at HLTH 2026, taking place through Wed., Nov. 18, at The Venetian Expo in Las Vegas. Co-Founder and CEO Landon Nattrass is sharingFaex Health’s first-of-its-kind approach to continuous gastrointestinal health monitoring to healthcare leaders, investors and strategic partners, demonstrating how artificial intelligence can help bridge a longstanding gap in preventive care by transforming everyday digestive health information into actionable insights.

Centered on the theme “The Age of Intelligent Healthcare Is Here,” HLTH 2026 brings together healthcare executives, clinicians, investors, technology innovators and policymakers to explore the technologies and partnerships shaping the future of healthcare delivery. Faex Health’s participation underscores the growing potential for AI-powered tools to make preventive health monitoring more accessible, continuous, and scalable.

Through computer vision and machine learning, the Faex platform analyzes smartphone images of stool alongside user-reported symptoms and other contextual information. The technology organizes digestive health indicators, identifies patterns, and tracks changes over time, helping users better understand their digestive wellness while supporting opportunities for more informed conversations with healthcare professionals.

“Healthcare has made tremendous advances in diagnosing and treating diseases, but we still overlook valuable information that people generate every day,” said Landon Nattrass, co-founder and CEO of Faex Health. “Our vision is to make digestive health monitoring as accessible and routine as tracking sleep, activity, or heart rate. HLTH brings together the organizations and decision-makers who can help move innovations like ours from promising technology into meaningful global healthcare applications.”

Unlike conventional approaches that often depend on periodic appointments, laboratory testing, or the onset of symptoms, Faex Health has developed technology designed to support ongoing digestive wellness tracking through a familiar device: the smartphone. The platform allows users to capture images, document symptoms, and review changes in digestive health indicators over time. Its AI-assisted tools provide structured wellness information and educational guidance intended to complement, rather than replace, professional medical evaluation.

“Faex Health is automatic and easy to use for both professionals and patients. For professionals, it allows us to review data quickly, verify each participant’s status, and keep the study under orderly control,” said Cristian Araya Orostica, registered nurse at Hospital Dr. Sótero del Río in Santiago, Chile, where Faex Health is participating in FECAL-AI, an ongoing clinical validation study evaluating its AI-powered technology for colorectal cancer prescreening.

Faex Health is exploring applications for healthcare providers, health plans, employers, and population health organizations seeking scalable approaches to preventive health engagement. The company’s broader platform strategy includes tools for organizing longitudinal digestive health information into structured summaries that may support clinical review and institutional health programs, subject to applicable requirements and validation.

As healthcare organizations increasingly evaluate artificial intelligence for preventive care, Faex Health is emphasizing the importance of responsible deployment, clinical validation, and appropriate integration with established healthcare practices. The company is also investigating potential applications of its technology in gastrointestinal prescreening and clinical research, including approaches that may help identify individuals who could benefit from additional medical evaluation. These investigational applications remain distinct from the company’s current wellness-monitoring capabilities and are not intended to replace established colorectal cancer screening, diagnostic procedures or professional medical judgment.

“The real opportunity for AI in healthcare is not simply generating more information. It is helping make meaningful information available at the right time, in a way that patients and healthcare professionals can actually use,” Nattrass added. “For health plans, employers and healthcare systems, that means exploring technologies that can encourage engagement, improve visibility into health trends and potentially reduce barriers to preventive care.”

During HLTH 2026, Faex Health is presenting the cutting-edge technology to healthcare organizations, investors, and collaborators interested in the intersection of artificial intelligence, digestive health, longitudinal monitoring, and population health. The company sees opportunities for its technology to complement existing healthcare systems by supporting accessible, non-invasive participation, and providing structured information that may help individuals and care teams recognize changes in digestive wellness over time.

Nattrass is available for media interviews regarding responsible AI in healthcare, the evolution of preventive health monitoring, the challenges of building clinically credible digital health technologies and the role of strategic partnerships in bringing emerging innovations to market.

For more information or to schedule an interview, contact Shawna Seldon at [email protected] or +1 917-971-7852.

About Faex Health
Faex Health is a health technology company that has developed AI-powered solutions for preventive gastrointestinal health monitoring. Using computer vision, machine learning, and smartphone-based image analysis, the Faex platform helps users capture digestive health information, monitor patterns over time, and access personalized educational wellness insights. The company has developed solutions designed to support individuals, healthcare providers, health plans, employers, and population health organizations. Faex Health’s investigational clinical applications are intended to complement established medical screening and diagnostic pathways, not replace them. For more information, visit FaexHealth.com. Continue the conversation on LinkedIn, Facebook, TikTok, X, Reddit, and Instagram.

SOURCE Faex Health

Numa Triples ARR, Raises $45M Series C to Run the Entire Dealership

Led by Blue Cloud Ventures, the round brings total funding to $96 million, with more than 1,500 dealerships across the U.S. and Canada already running on Numa’s AI Operating System

SAN FRANCISCO, Nov. 16, 2026 — Numa, the AI Operating System for dealerships, today announced a $45 million Series C led by Blue Cloud Ventures, with participation from Threshold Ventures, Costanoa, Touring Capital, Gradient Ventures and Tokio Marine Future Fund. The round brings Numa’s total funding to $96 million. It caps a year in which Numa tripled in size, tripled its annual recurring revenue and became the AI system GM, FordDirect, BMW and Stellantis each put in front of their dealerships.

Numa has already won the hardest part of the dealership: the customer conversation. The system has handled more than 1 billion calls, texts and chats and booked more than 4 million appointments. Dealerships that run on Numa stay and grow with it. Net revenue retention has risen over the past year, and more dealerships are moving to longer agreements.

For decades, dealership software was built one task at a time. Each system kept its own record of what happened, and none of them acted on what the customer just said. The first wave of AI did not change that. It answered faster, then handed the work back to people to chase by hand.

Numa does not hand the work back. It knows not just who the customer is but what they need, and it acts on it: booking the visit, finding the right car, routing the call or flagging the customer about to leave.

“In two years, every general manager will have an AI COO,” said Tasso Roumeliotis, founder and CEO of Numa. “At more than 1,500 dealerships, they already do, and it is Numa. It knows every conversation in the store, sees what needs attention and runs the work that follows. That is not another dashboard or another point tool. It is an operating system. The DMS was built to record the dealership. It was never built to run it. Numa was, and this round puts more engineers to accelerate it.”

“What is unique about Numa is that the company understands the DNA and culture of a dealership and seamlessly AI-enables the workflow while empowering all constituents including the dealerships customers”, added Mir Arif, Managing Partner of Blue Cloud Ventures.  “Numa is not prescriptive but rather deeply understands the objectives of the BDC representative, the salesperson, the service technician, the parts specialist and the sales manager and significantly enhances their productivity.” 

“As an insurer, we view dealerships as a critical part of the ecosystem that supports customers throughout their vehicle ownership journey,” said Mitsutoshi Shizuru, Managing Executive Officer of Tokio Marine & Nichido Fire Insurance Co., Ltd, “Numa is using AI to make this important customer touchpoint faster, more efficient, and more seamless. We believe Numa’s technology has the potential to revolutionize the relationship between dealerships and their customers and help shape the next generation of mobility customer experiences in the U.S. and beyond.”

This year, Numa took its system across the whole store.

In the service lane, Numa already knows every conversation. In August, Numa acquired SocketTime to put the work behind those conversations into the same system, so what a customer tells the store and what the store does about it run in one place.

In sales, Numa for Sales, launched this month, as the first agent with Inventory Fluency. It knows every new and used vehicle on the lot down to the trim, features and miles, learns each buyer’s situation and gets them in the car that fits best, even when the one they called about has sold. Every qualified lead lands in the dealership’s CRM with the full conversation, so the salesperson who picks it up already knows the buyer.

On every line into the store, Operator, launched in September, is the first Precision Routing system for dealerships. It answers first, understands why each customer is calling and puts them in the right hands with that reason carried through. When the phone rings, everyone at the dealership knows the call is for them. Operator continues to climb above 95% with calls going to the right destination.

LiveCSI™ reads customer interactions as they happen and flags the ones putting satisfaction at risk while there is still time to fix them, instead of waiting for a survey to report what went wrong. In 90 days, it analyzed 50 million interactions.

Every dealership on Numa now has over 25+ natural voices to choose from, with regional accents, a new Spanish voice, sharper recognition of vehicle makes, models and VINs, and adjustable speaking speed. The voice on the line sounds like someone who works at the dealership. It comes at no added cost, with nothing for the store to set up.

Three of the largest automakers in North America have each chosen Numa. GM named Numa an iMR Approved Turnkey Vendor, and more than 240 GM dealerships run on Numa today. In those stores, reply times have dropped from 23 hours to 24 minutes, each store saves about $11,000 a month, and 86% of customers flagged as heat cases return for service within six months. FordDirect selected Numa as its strategic AI vendor, making Numa available to more than 3,000 Ford and Lincoln dealerships. Numa is also approved on Stellantis’ MarketCenter, opening access to more than 2,600 dealerships in the U.S. and 440 in Canada.

The operating system for the dealership is not on its way. It is already running.

To learn more, visit numa.com.

About Numa

Numa is the AI Operating System used by leading dealerships to modernize customer operations across voice, text, service, sales, fixed operations, and customer intelligence. Built for the complexity of dealership workflows, Numa combines AI agents, human-in-the-loop collaboration, operational intelligence, and LiveCSI™ to help dealerships respond faster, improve customer experience, increase productivity, identify store-level patterns, and run more intelligently.

Numa answers every call, books appointments, and protects CSI in real time, unifying every customer conversation across voice, text, and digital channels in one system.

Trusted by more than 1,500 dealerships across the U.S. and Canada, Numa is based in Silicon Valley and was founded by the team behind Location Labs. The company has raised $96 million from investors including Blue Cloud Ventures, Google, Threshold Ventures (founding investor of Tesla), Mitsui, Costanoa Ventures, Touring Capital, and Tokio Marine Future Fund. Inc. 5000 recognized Numa as the #443 fastest-growing company overall and the #1 fastest-growing dealership software company.

About Blue Cloud Ventures

Blue Cloud Ventures is a New York City-based venture growth firm that invests in leading AI software, AI infrastructure and cybersecurity companies. BCV has a track record of supporting visionary entrepreneurs from growth to exit, with a portfolio of over 55 category-defining software companies in the United States and Europe.

SOURCE Numa

Remedy Robotics Raises $62 Million Series B to Bring Life-Saving Cardiovascular Intervention to Patients Everywhere

Funding will support clinical trials, advancement toward FDA approval, and planned commercial deployment of the company’s AI-enabled endovascular robotic platform and software suite

SAN FRANCISCO, Nov. 16, 2026 — Remedy Robotics, Inc. (“Remedy”), a leading healthcare and physical AI company developing robotic systems for cardiovascular care and endovascular intervention, today announced it has raised $62 million in Series B funding to accelerate its mission of delivering flawless, immediate robotic care to all patients, regardless of location.

The funding will support several major milestones, including a planned pivotal clinical trial in partnership with the University of California and advancement toward FDA approval for neurovascular intervention. Remedy will also deploy prototype N1 Systems across its network of clinical partners, including through its strategic partnerships with SVIN Mission Thrombectomy and the Australian Stroke Alliance, while continuing to advance the system’s industry-leading AI capabilities and autonomous functions.

“Endovascular intervention is the gold standard treatment for stroke and many cardiovascular emergencies, yet access remains limited to a small number of hospitals. For these time-critical conditions, that’s devastating. Even when specialist intervention is available, treatment is often delayed, and complications are frustratingly common,” said Dr. David Bell, CEO and Co-founder of Remedy Robotics. “This funding will allow us to accelerate toward deployment of our N1 System so we can bring quality intervention to patients everywhere, regardless of geography.”

DCVC led the Series B, with participation from new investors including UC Investments (the University of California’s investment office), Skip Capital, and Hostplus (one of Australia’s largest pension funds). Existing investors Build Collective by Tony Fadell, Blackbird, Divergent Capital and KdT Ventures doubled down.

“Remedy Robotics represents a new generation of medical robotics and physical AI companies, focused not only on technical innovation, but on solving real-world challenges,” said James Hardiman, General Partner at DCVC. “We believe the company is uniquely positioned to redefine how life-saving intervention is delivered and are thrilled to support them as they advance toward broader clinical and commercial adoption.”

Remedy is finalizing development of the N1 System, an AI-enabled robotic platform and software suite that uses machine learning to analyze preoperative imaging, simulate cases in advance, provide real-time 3D-2D image registration and complete entire endovascular procedures robotically. Designed for on-site, remote, or autonomous operation, the system has the potential to dramatically expand access to and improve the quality of specialized neurovascular, coronary, and peripheral vascular care. Remedy now works with more than 100 hospitals worldwide and is among a small group of physical AI companies bringing robotics into real-world clinical use. In October 2025, Remedy announced that it had successfully completed the world’s first remote neurointerventional procedures using the N1 System.

“This funding will allow our world-leading hardware, software, and machine learning teams to progress the N1 system towards clinical trials and potential FDA approval, while also developing additional features including full autonomy,” said Jake Sganga, CTO and Co-founder of Remedy Robotics. “We are particularly excited to deepen our partnership with the University of California, having worked closely with their clinical experts since 2021, and as we prepare for our planned pivotal clinical trials to be held across the UC network.”

“Remedy is building the kind of company we look for at Blackbird: one with world-class technical talent, a massive global problem to solve, and the potential to create an entirely new category,” said Michael Tolo, Partner at Blackbird. “We believe Remedy is uniquely positioned to transform how endovascular care is delivered, and we are excited to support the company through its next phase of growth.”

Cardiovascular disease, including stroke and heart attack, is the leading cause of death globally—claiming nearly 20 million lives each year—about twice the toll of all cancers. Beyond the human cost, stroke alone carries an annual economic burden of approximately $891 billion worldwide through healthcare costs and lost productivity. Access to endovascular intervention, the most effective treatment for many cardiovascular conditions, remains severely limited because only highly specialized physicians at a small number of hospitals can perform it. Today, just 2.8 percent of eligible stroke patients worldwide have access to endovascular treatment, leaving millions each year with otherwise preventable disability. Because cardiovascular emergencies are so time-critical, patient outcomes vary sharply based on proximity to specialized care, even in countries with well-developed specialist networks, such as the United States. Remedy’s technology directly addresses this access gap, delivering expert care for stroke, severe heart attacks, hemorrhagic conditions, and other time-critical cardiovascular emergencies to patients wherever they are.

Remedy aims to elevate the standard of care across the cardiovascular continuum, from diagnosis to discharge and surveillance, with the goal of making flawless, immediate cardiovascular care available to patients everywhere, from San Francisco to rural areas of Arkansas where timely care is out of reach, or to Lagos, Nigeria, where intervention is almost entirely unavailable.

The N1 System is under development and is not currently available for sale or clinical use in any jurisdiction.

About Remedy Robotics
Remedy Robotics is a leading healthcare and physical AI company developing AI-enabled endovascular robotic systems and software for on-premise, remote, and autonomous intervention. Its proprietary N1 System combines robotics, AI, and advanced computer vision to raise the standard of care across the cardiovascular continuum—from diagnosis and intervention to discharge and surveillance—bringing expert-level treatment within reach of patients wherever they are. Remedy’s clinical and research work has been published in leading peer-reviewed journals, including Interventional Neuroradiology and the American Journal of Neuroradiology, and the company holds 48 patents covering its platform, including foundational patents in machine learning applied to surgical robotics. Headquartered in San Francisco, Remedy is backed by DCVC, Blackbird, UC Investments (the University of California’s investment office), and Tony Fadell’s Build Collective, among others, and partners with clinicians at leading medical institutions across the U.S. and worldwide. Remedy is also the exclusive robotic partner of SVIN Mission Thrombectomy, a global initiative dedicated to expanding access to stroke treatment worldwide. Learn more at www.remedyrobotics.com.

SOURCE Remedy Robotics, Inc.

Accountable Launches to Give Power to American Taxpayers

Co-founded by Acorns CEO Noah Kerner and Jeff Cruttenden, Accountable raises $20 million to help Americans file their taxes, follow their money, and ultimately decide how it is spent.

NEW YORK, Nov. 16, 2026 — Accountable, a new consumer tax and civic company, launched its waitlist today with the belief that taxpayers should be treated like investors in the country they fund. Investors expect transparency into how their money is put to work, accountability for how it is managed, and a voice in the decisions that shape where it goes. Taxpayers deserve the same.

Every year, Americans file more than 160 million federal income tax returns, while individuals— not corporations—account for roughly 85% of federal tax revenue. The average taxpayer spends about 12 hours preparing and completing a return, only to be left with a larger question once it’s filed: what did their money actually pay for?

Accountable’s first product, a tax filing platform designed around the needs of the taxpayer, will launch in January 2027 ahead of tax season. With a filer’s permission, Accountable retrieves available tax information and documents, prefills their return, and guides them through reviewing and submitting for one flat price of $76, with filing free for anyone experiencing financial hardship. Accountable customers will also receive a personalized taxpayer receipt showing an estimated breakdown of what their taxes fund across federal, state, and local government spending.

“Cumulatively, taxes are the largest check most of us will ever write, and it’s ridiculous that we don’t even get a receipt,” said Noah Kerner, co-founder of Accountable. “Taxpayers deserve a better experience: smart, fast and fair filing, transparency into what we’re paying for, and power over where our money goes. After all, it’s our money, we fund this country, and we should feel like shareholders in it.”

The filing platform is the first step in Accountable’s broader vision: help Americans file their taxes, follow their money and, over time, have a greater voice in how it is spent. Accountable is starting with filing because it is the most direct financial interaction most Americans have with government. Each year, Americans are asked to account for every dollar they earn. Accountability should go both ways.

For Kerner, Accountable is a continuation of a career spent giving everyday people more access and agency in complex financial systems. At Acorns, Kerner has helped over 15 million everyday Americans save & invest over $30 billion. At Say, he gave individual investors a voice in the companies they own. At Accountable, he wants to give taxpayers the same voice in the country they fund. The full team behind Accountable comes with a wealth of experience across tax, civic, investing, health, and consumer technology sectors.

“We backed Accountable because we believe the taxpayer is one of the biggest consumer categories still waiting to be reinvented,” said Lauren Kolodny, Founding Partner at Acrew Capital. “Noah has spent his career earning the trust of everyday Americans. With Accountable, he’s bringing that same consumer-first mindset to one of the most important financial relationships in their lives.”

“Americans have more tools than ever to understand where their money goes, except when it goes to the government,” said Brent Murri, Partner at M13. “At M13, we look for founders who transform complex, entrenched systems into experiences that give people greater control. Accountable has the potential to fundamentally change the relationship between Americans and the government they fund.”

Accountable has raised $20 million in total funding, including a seed round co-led by Acrew Capital and M13, with participation from Greycroft, Torch Capital, Treasury, 645 Ventures, Eniac Ventures, Lerer Hippeau, Tusk Ventures, and angel investors like Josh Wolfe, founder of Lux Capital, and Zach Perret, co-founder of Plaid. The capital will support the buildout of Accountable’s filing platform and team ahead of its January launch. Kerner will continue to serve as CEO of Acorns.

Americans can join the waitlist beginning today at AccountableUSA.com.

About Accountable
Accountable is a consumer tax and civic company on a mission to bring Americans closer to America. Its first product, a tax platform designed to give Power to the Taxpayer, launches for the 2027 tax season. Join the waitlist at AccountableUSA.com.

SOURCE Accountable

Windward Bio Lists on Nasdaq, Shares Up 68% on Debut

Pivotal bioVenture Partners China-backed biotech built under the NewCo model on China-licensed assets debuts on Nasdaq less than two years after founding

SHANGHAI, Nov. 16, 2026 — Windward Bio Group AG (Nasdaq: WWB), a clinical-stage biotechnology company and a portfolio company of Pivotal bioVenture Partners China, began trading on the Nasdaq Global Select Market on Nov. 13, 2026. The company priced its initial public offering at $17.00 per share and sold approximately 10.29 million ordinary shares, raising $225 million in gross proceeds, including a $50 million concurrent private placement from Sanofi. Windward closed its first day of trading with a market capitalization of approximately $1.69 billion.

Windward was founded in 2024 by serial entrepreneur Luca Santarelli, M.D., and his team, whose prior companies VectivBio and Therachon were both acquired. Since inception, the company has raised $365 million, including a $200 million Series A in January 2025 and a $165 million crossover financing in May 2026. Pivotal bioVenture Partners is among the investors that have backed Windward through every financing round since its earliest days, from formation to a Nasdaq listing in under two years.

Headquartered in Basel, Switzerland, Windward develops ultra-long-acting antibody medicines for serious respiratory and dermatologic diseases, including asthma, chronic obstructive pulmonary disease (COPD) and atopic dermatitis. Its lead program, WIN378, is an ultra-long-acting, fully human monoclonal antibody against thymic stromal lymphopoietin (TSLP) now advancing through POLARIS-1, a Phase 2/3 study in asthma, and SIRIUS, a Phase 2 study in COPD. Designed for twice-yearly dosing, versus the once-every-four-weeks regimen of currently approved agents, WIN378 could meaningfully ease the long-term treatment burden for patients with chronic airway disease. In September 2026, the company reported positive interim Phase 2 data supporting twice-yearly dosing of WIN378 in asthma. Windward’s pipeline also includes WIN027, a clinical-stage bispecific antibody targeting TSLP and IL-13 now in Phase 1 development.

The global rights (excluding Greater China and certain Asian markets) to both of Windward’s core programs were licensed from Chinese biopharmaceutical companies. WIN378 (HBM9378/SKB378) came out of a co-development program between Harbour BioMed and Kelun-Biotech, while WIN027 (QX027N) was licensed from Qyuns Therapeutics. Windward is the latest example of China-originated drug candidates reaching global capital markets through license-out deals.

Windward is a leading case of the NewCo model in the current wave of Chinese biotech going global: a global investment firm leads the spin-out and licensing of a Chinese company’s pipeline asset, sets up a new entity overseas, and arms it with international capital and an experienced operating team to run clinical development and commercialization worldwide — typically excluding Greater China. Pivotal bioVenture Partners China’s practice has been a consistent investor, participating in the $200 million Series A in January 2025, increasing its position in the $165 million crossover round in May 2026, and remaining a shareholder through the IPO. In less than two years, Windward has completed the full path from “China asset licensing” to “NewCo formation” to “global financing” to “IPO listing,” plugging China-originated innovation into the global value chain.

According to company disclosures, net proceeds from the offering will be used primarily for completing core clinical development of WIN378, including the Phase 2/3 and confirmatory asthma studies and the Phase 2 COPD study; advancing the global Phase 2b COPD trial and the Phase 2 atopic dermatitis trial of WIN027, the latter expected to begin enrollment in the first half of 2027; moving the bispecific program to Investigational New Drug (IND) readiness; and funding working capital and general corporate purposes. After the offering, the pipeline is expected to reach three key data milestones: top-line Phase 2 asthma data for WIN378 (POLARIS-1) in the first half of 2027, Phase 2 COPD data (SIRIUS) in the second half of 2027, and Phase 3 asthma data in the first half of 2029.

For Pivotal bioVenture Partners, Windward Bio is a prime example of the NewCo model at work — China-originated innovation matched with global capital and world-class execution. From the start, the firm saw WIN378 and WIN027 as potential best-in-class, ultra-long-acting biologics for serious respiratory and dermatologic diseases, and it has backed Luca Santarelli and his team through every financing round since formation. The Nasdaq listing in under two years — putting the value of assets originated by its Chinese partners Harbour BioMed, Kelun-Biotech and Qyuns Therapeutics on the global stage — is a milestone for Pivotal, which plans to keep supporting Windward through its next phase of growth.

About Windward Bio

Windward Bio is a clinical-stage biotechnology company with deep drug discovery, development and commercialization experience, focused on transforming the treatment of serious immunological diseases, including respiratory and dermatologic conditions. Its lead program, WIN378, is an ultra-long-acting anti-TSLP monoclonal antibody with best-in-class potential, now in Phase 2/3 clinical trials for asthma. The company’s pipeline also includes WIN027, a clinical-stage, long-acting anti-TSLP×IL-13 bispecific antibody with broad therapeutic potential across inflammatory diseases, now in Phase 1. Windward is also building a long-acting bispecific antibody discovery pipeline focused on validated targets in respiratory and dermatologic diseases.

About Pivotal bioVenture Partners

Pivotal bioVenture Partners was founded by Hong Kong’s Nan Fung Group. Since launching its U.S. operations in 2017 and its China practice in 2018, Pivotal has built broad international reach and global resource-coordination capabilities. The firm seeks out innovative products and technologies worldwide, founding and investing in leading life-science companies in Greater China to meet growing medical needs in global markets — particularly China. Pivotal invests across biopharmaceuticals, medical devices and healthcare services. Its team of seasoned life-science investors and entrepreneurs brings deep industry experience in company creation and venture investment.

Contact:
Phone: +86-21-68503033
Email: [email protected]

SOURCE Pivotal bioVenture Partners China

Gemspring Capital Closes Fourth Buyout Fund at $3.5 Billion Hard Cap

WESTPORT, Conn., Nov. 16, 2026 — Gemspring Capital Management, LP (“Gemspring”), a middle-market private equity firm, today announced the formation of its fourth buyout fund, Gemspring Capital Fund IV, LP (“Fund IV”), at $3.5 billion. Fund IV was oversubscribed and reached its hard cap in less than three months, holding a single close on all institutional limited partner commitments.

“We are grateful for the strong support from both our existing and new limited partners,” said Bret Wiener, Founder and CEO of Gemspring. “The successful fundraise reflects the strength of our team, our differentiated investment approach, and our track record of building great businesses.”

Consistent with prior funds, the Gemspring team made a substantial capital commitment to Fund IV, making it the Fund’s largest single investor.

Gemspring also manages Gemspring Growth Solutions, a complementary non-control investment strategy that closed its second fund at $1.1 billion in 2025.

Sidley Austin LLP served as legal counsel to Gemspring in connection with Fund IV.

About Gemspring Capital

Gemspring Capital, a Westport, Connecticut-based private equity firm with approximately $9 billion of capital under management, provides flexible capital solutions to middle-market companies. Gemspring partners with talented management teams to accelerate growth, drive value creation, and build great businesses. Target companies have up to $2.0 billion in revenue and operate across the aerospace & defense, business services, consumer services, financial and insurance services, healthcare, industrial, software, and tech-enabled services sectors. For more information, visit www.gemspring.com.

Contact: Jack Tucker, [email protected]

SOURCE Gemspring Capital


Halifax Group Named to Inc.’s 2026 Founder-Friendly Investors List for Fourth Consecutive Year

Recognition underscores the firm’s longstanding commitment to partnering with founders and family-owned businesses

WASHINGTON, Nov. 16, 2026 — Halifax Group (“Halifax”), a middle-market private equity firm that partners with management to invest in market-leading companies, announced today that it has been named to Inc.’s 2026 Founder-Friendly Investors list for the fourth consecutive year. The annual list recognizes private equity firms, venture capital firms, and lenders with strong track records of supporting entrepreneurs and helping founder-led businesses grow.

Now in its eighth year, Inc.’s Founder-Friendly Investors list honors 294 firms that support entrepreneurs and remain actively involved in the businesses they back.

“Four years in a row is a reflection of the founders and families who have trusted us with their companies,” said Chris Cathcart, Managing Partner at Halifax. “Our approach has not changed: we listen first, align on a clear plan, and then do the work alongside management. We are grateful to the entrepreneurs who shared their experience with Inc., and we remain committed to being the kind of partner they would choose again.”

Since its founding in 1999, Halifax has invested in more than 22 founder- and family-owned companies. The firm focuses on investments across health and wellness, outsourced business services, and franchising, partnering with management teams to support strategic growth and long-term value creation.

Inc.’s Founder-Friendly Investors list recognizes investors that back founder-led businesses and help them grow. To qualify for the main list, firms must have exited at least one U.S.-based, founder-led portfolio company since January 1, 2021. Inc. surveyed founders of portfolio companies that exited within the past five years, reviewed portfolio company growth data, and combined those findings with editorial research to produce a proprietary score. Halifax submitted examples of founder-led investments and its value creation approach, and paid a fee to Inc. to submit an entry this year and all previous years selected. This award reflects the opinion of Inc. and is not indicative of future performance. The complete list is available at https://www.inc.com/founder-friendly-investors/2026. 

About Halifax Group

Founded in 1999, Halifax Group is a private equity firm that partners with managers and entrepreneurs to recapitalize and invest in lower middle-market businesses with total enterprise values generally between $100 million and $300 million. Halifax specializes in equity recapitalizations, corporate carve-outs and management buyouts and invests across a variety of industries, including health and wellness, outsourced business services and franchising. The firm is headquartered in Washington, D.C., and maintains an office in Raleigh, North Carolina.

Contact
LLYC
Christina Maldonado
[email protected]  

SOURCE Halifax Group

LongueVue Capital Launches Sports & Entertainment Investment Strategy, Names Doug Thornton Operating Partner

New Orleans investment firm will partner with founder-owned companies that serve teams, leagues, venues, colleges, and fans

NEW ORLEANS, Nov. 16, 2026 — LongueVue Capital (“LVC”), a New Orleans-based private equity firm that has focused on partnering with founders and entrepreneurs for 25 years, today announced the launch of a dedicated Sports & Entertainment investment strategy. LVC will invest in middle-market companies that provide services, products, and experiences to teams, leagues, venues, colleges, and fans. Doug Thornton, former President of North American Venues for Legends Global and longtime leader of the Caesars Superdome, has joined LVC as Operating Partner to help lead the effort.

Sports and entertainment has become one of the most resilient parts of the consumer economy. Venues are in decades-long modernization cycles and are evolving into year-round destinations. Teams, leagues, and universities are outsourcing more specialized work to best-in-class partners, while spending on amateur sports and live events continues to grow. These are fundamentally human experiences: technology, including AI, can enhance them, but it cannot replace them.

While many sports investment firms have concentrated on franchise stakes and bigger transactions, much of the industry is built by founder-owned companies, from event production firms to venue service providers, that have reached the scale where they need both capital and a strategic partner. LVC sees a clear gap in the middle market and a natural fit with its long history of helping entrepreneurs professionalize and grow their businesses.

LVC will focus on five areas: live event production and experiential services; venue support services; youth and amateur sports; commercial services for teams and leagues; and fan engagement platforms. LVC generally targets companies with $10 million to $100 million in revenue.

“Some of the best businesses in sports are the ones fans never see: the companies that produce the show, run the building, and help teams sell the experience,” said Ryan Nagim, Managing Partner and Head of Sports & Entertainment at LVC. “Many of those companies are founder-built and ready for a partner that understands their industry. That’s the role we’ve played for entrepreneurs for 25 years, and Doug gives us real industry depth from day one. I’ve known him for more than 15 years. His relationships across the industry are unmatched, and he shares our belief that great outcomes come from unique and genuine partnerships with founders and their leadership teams.”

Doug Thornton brings four decades of experience in sports, live entertainment, and venue management. Most recently as President of North American Venues for Legends Global, Doug oversaw the operation of more than 200 stadiums, arenas, theaters, and convention centers. He was named General Manager of the Louisiana Superdome (now Caesars Superdome) in 1997 and led its rebuilding after Hurricane Katrina and its reopening in 2006, the largest stadium reconstruction project in U.S. history. Through his career with SMG, ASM Global, and Legends, Doug has built relationships with leagues, teams, collegiate athletic programs, live entertainment producers, and the executives who run them.

“Throughout my career, I’ve seen how much teams, leagues, and venues rely on outside partners to deliver for fans and athletes, and many of those partners are entrepreneur-built businesses,” said Doug Thornton. “LVC has a long track record of helping founders take their companies to the next level through a true partnership mentality. I’ve known this team for years, I believe in their culture, and I’m excited to bring that approach to the industry where I have spent my career.”

This strategy follows a model that LVC has used for years: deploying highly tailored, thematic investment theses with dedicated, seasoned industry executives who help source opportunities and work hands-on with management teams post-closing to drive value creation. LVC’s partnerships are built on conservative capital structures, significant growth capital, and meaningful ownership for management teams.

Founders, management teams, and advisors with opportunities in the sector can contact Charles Cox, Partner and Head of Business Development, at [email protected] or 504.293.3600.

About LongueVue Capital

Founded in 2001, LongueVue Capital is a New Orleans-based private equity firm that partners exclusively with founders and entrepreneurs in the middle market. With over $1 billion of committed capital spanning five funds, LVC provides growth capital, hands-on operating support, and a team of dedicated operating partners with deep industry experience to help companies professionalize and scale. The firm invests across healthcare, transportation and logistics, industrial services, consumer, food and beverage, and sports and entertainment. LVC is backed primarily by institutional and family office investors in addition to current and former portfolio company executives. In 2024, LVC was recognized by Bloomberg as the No.1-performing growth equity fund under $500 million among funds with vintages from 2015 to 2020.

For more information, visit www.lvcpartners.com and www.lvcpartners.com/portfolio/sports-entertainment.

Media Contact
For media inquiries, please contact:
Elizabeth Roper [email protected]
Charles Cox [email protected]

SOURCE LongueVue Capital

Stark Future avslutar finansieringsrunda på över 150 miljoner euro i totalt transaktionsvärde när dess elmotorcyklar går om förbränningsmotorn på världsscenen

Rundan leds av Highland Europe tillsammans med Morgan Stanley Investment Managements 1GT och Axon Partners Group, med deltagande från befintliga och nya investerare.

BARCELONA, 16 november, 2026 — Stark Future, Barcelonaföretaget bakom världens mest sålda enduromotorcykel, meddelar i dag att bolaget har avslutat en finansieringsrunda med ett totalt transaktionsvärde på över 150 miljoner euro, den största investeringen någonsin i ett europeiskt elmotorcykelföretag. Rundan värderar Stark Future till 1,2 miljarder euro före investeringen (pre-money), vilket gör bolaget till Europas första elmotorcykelföretag med en värdering över 1 miljard euro. Rundan leddes av Highland Europe tillsammans med 1GT, Morgan Stanley Investment Managements strategi för klimatinriktat private equity, och det Spanienbaserade internationella investmentbolaget Axon Partners Group, med deltagande från befintliga aktieägare samt vänner och familj. Rundan blev övertecknad och överträffade det ursprungliga målet, vilket fick bolaget att hålla dörren öppen för en andra stängning för att ge plats åt ytterligare strategiska partner, bland andra Lombard Odier.

Stark Future grundades 2020 utifrån en kompromisslös övertygelse om att elmotorcykeln inte bara ska vara det gröna alternativet, utan den bättre maskinen. Bolaget bygger motorcyklar som är utformade för att slå de bästa förbränningsmotorcyklarna i varje kategori bolaget ger sig in i. I dag konstrueras, utvecklas och tillverkas VARG-plattformen, som omfattar motocross, enduro och supermoto, helt i egen regi i bolagets 20 000 m² stora anläggning i utkanten av Barcelona. Det nya kapitalet ska finansiera global expansion och utvecklingen av nya elektriska plattformar.

På bara tre års försäljning har Stark gått från utmanare till ledare i sin kategori. VARG är i dag världens mest sålda enduromotorcykel och säljer mer än varje konkurrent med förbränningsmotor. Redan under det första året tog Stark omkring 50 procent av enduromarknaden i Tyskland och förstaplatsen i Frankrike och Italien, samtidigt som USA har vuxit till bolagets största marknad sett till volym. Från noll har Stark på tre år tagit omkring 5 procent av den globala offroadmarknaden för motorcyklar, värd 3 miljarder euro, från förbränningsmotorn. Det nya kapitalet ska användas för att upprepa det, och mer därtill, genom att gå in i nya motorcykelkategorier på en betydligt större adresserbar motorcykelmarknad värd 90 miljarder euro. Få hårdvaruföretag växer så här snabbt. Ännu färre gör det med lönsamhet.

Anton Wass, grundare och vd för Stark Future, säger: “För sex år sedan var Stark en orubblig övertygelse om att el kunde vara den bättre maskinen, inte kompromissen. I dag är det den största investeringen någonsin i ett europeiskt elmotorcykelföretag. Vi vände upp och ner på branschen en gång med VARG och tog 5 procent av en marknad värd 3 miljarder euro från förbränningsmotorn på tre år. Nu har vi resurserna att göra det igen, och mer därtill, på en marknad värd 90 miljarder euro. Medan andra i branschen har tvingats ge upp har vi vuxit, blivit lönsamma och fått med Highland Europe och världsledande institutionella investerare, och vi har hållit dörren öppen i den andra stängningen för ytterligare några som delar samma ambition. Inget av detta hade varit möjligt utan förarna som valde en VARG innan världens största investerare gjorde det, och återförsäljarna som ställde in den i sina butiker. Tack för att ni har gjort den här drömmen verklig. Vi är inte här för att delta i motorcykelns framtid. Vi är här för att leda den.”

Tony Zappalà, partner på Highland Europe, tillägger: “Sedan Stark Future sålde sin första motorcykel för bara tre år sedan har bolaget blivit det självklara namnet inom prestandainriktad offroadmotorcykling. Det har byggt upp den positionen i marknadens mest tekniska och krävande segment. När vi träffade Anton och teamet smittades vi direkt av bolagets vägledande princip: att bygga den bästa motorcykeln utan kompromisser. Motorcyklar är den sista stora fordonskategorin som på allvar genomgår elektrifiering. Många har försökt, men ingen har nått Starks framgång. Vi tror att Stark blir det företag som leder omställningen med prestanda i världsklass.”

Vikram Raju, chef för klimatinriktade private equity-investeringar på Morgan Stanley Investment Management och 1GT, säger: “De mest övertygande klimatlösningarna är ofta de som inte kräver att kunderna kompromissar. Stark Future är ett tydligt exempel på det och kombinerar ett ständigt fokus på teknisk excellens med elmotorcyklar som är byggda för att i första hand konkurrera med prestanda. På 1GT stöttar vi ambitiösa grundare och team vars produkter och lösningar har potential att skapa verklig påverkan och driva på omställningen till en koldioxidsnålare ekonomi. Vi ser fram emot att stödja bolaget i nästa tillväxtfas och att bidra med Morgan Stanleys resurser och globala kapacitet till partnerskapet när Stark fortsätter att växa internationellt.”

Alfonso de León, Managing Partner på Axon Partners Group, säger: “Stark är det sällsynta teknik- och prestandaföretaget som växer som ett techbolag och tjänar pengar som ett industriföretag. Som Spanienbaserat investmentbolag är Axon stolta över att investera tillsammans med Highland, 1GT och en grupp investerare i världsklass för att stötta ett spanskt företag som leder en global kategori. Det här är bara början på vad Stark kommer att bli.”

Stifel var ledande finansiell rådgivare till Stark Future i transaktionen. Investeringen ger långsiktigt stöd från stora institutionella investerare, däribland Highland Europe, vars portfölj omfattar kategoriledande företag som Wolt, GetYourGuide, Huel och Zwift, tillsammans med Morgan Stanley Investment Managements strategi 1GT, Axon Partners Group och Lombard Odier. Tillsammans ger de Stark Future kapitalet och räckvidden för att göra ledarskapet inom elektrisk offroad till en global kraft inom motorcykling.

Om Stark Future

Stark Future är ett Barcelonabaserat företag inom premiumelmotorcyklar och teknik, grundat 2020. Bolagets strategi är att bygga elmotorcyklar som överträffar de bästa förbränningsmotorcyklarna i varje kategori. Flaggskeppsplattformen VARG, som omfattar motocross, enduro och supermoto, inkluderar världens mest sålda enduromotorcykel, som säljer mer än varje konkurrent med förbränningsmotor. Varje motorcykel byggs i bolagets egen 20 000 m² stora anläggning utanför Barcelona, och Stark tävlar på högsta nivå världen över, bland annat i FIM SuperEnduro, Hard Enduro, EnduroGP och World Supercross Championship.

Mer information finns på https://starkfuture.com.

Kontakt: Benjamin Cobb, Director Brand Communications, Stark Future, [email protected]